• Angiographic endpoint of in-stent late lumen loss as measured by QCA. [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  

• Target Lesion Failure defined as cardiac death that cannot be clearly attributed to a non-cardiac event or non-target vessel, target vessel related myocardial infarction or clinically driven target lesion revascularization. [ Time Frame: hospital discharge, 30 days, 6 months and annually through five years. ] [ Designated as safety issue: Yes ]
  
• Target Vessel Failure defined as any myocardial infarction or cardiac death that cannot be attributed to a non-target vessel or any target vessel revascularization. [ Time Frame: Hospital discharge, 30 days, 6 months and annually through five years ] [ Designated as safety issue: Yes ]
  
• Major Adverse Cardiac Events defined as an adjudicated composite of death, emergent coronary artery bypass graft surgery, target lesion revascularization, or new myocardial infarction. [ Time Frame: Hospital discharge, 30 days, 6 months and annually through five years ] [ Designated as safety issue: Yes ]
  
• Incidence of stent thrombosis [ Time Frame: Hospital discharge, 30 days, 6 months and annually through five years ] [ Designated as safety issue: Yes ]
  
• Incidence of target lesion revascularization and target vessel revascularization. [ Time Frame: Hospital discharge, 30 days, 6 months and annually through five years ] [ Designated as safety issue: Yes ]
  
• Device Success [ Time Frame: Procedural ] [ Designated as safety issue: No ]
  
• Lesion success [ Time Frame: Procedural ] [ Designated as safety issue: No ]
  
• Procedure Success [ Time Frame: Hospital Discharge ] [ Designated as safety issue: Yes ]
  
• Angiographic in-stent and in-segment binary restenosis. [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  
• In-stent minimum lumen diameter [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  
• Percent volume obstruction of the stent by intravascular ultrasound evaluation [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  
• Patient reported outcomes as measured by three standardized quality of life surveys. [ Time Frame: Baseline, 30 days, 6 months and 12 months ] [ Designated as safety issue: No ]
  

Restenosis remains a frequent cause of late failure following successful coronary angioplasty occurring in an estimated 20-40% of procedures performed. Coronary stents provide mechanical scaffolding that helps reduce restenosis by limiting the extent of elastic recoil and late vascular remodeling. Despite improvements over balloon angioplasty alone, restenosis following coronary stenting procedures has been cited to occur in 20-40% of cases and is primarily a result of neointimal hyperplasia. Thus, stents which are capable of delivering drugs to limit neointimal hyperplasia, in addition to providing mechanical support at the area of the lesion, have been developed to further limit the extent of restenosis following coronary stenting. There are several pharmacologic agents approved for use with drug-eluting stents.Two drugs have been widely studied in controlled clinical trials and real-world patient populations, sirolimus and paclitaxel.

This study will evaluate a new sirolimus-eluting cobalt chromium coronary stent system compared to an approved paclitaxel-eluting coronary stent system in the treatment of single de novo coronary lesions in native coronary arteries. Subjects meeting qualification will be randomized in a 1:1 fashion to treatment with the Conor sirolimus-eluting coronary stent or to treatment with an approved paclitaxel-eluting coronary stent. All subjects will undergo angiographic follow-up at six months and complete clinical follow-up for a period of five years.